1. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro
- Author
-
Jerome Canady, Olivia Jones, Xiaoqian Cheng, Lawan Ly, Michael Keidar, Taisen Zhuang, Giacomo Basadonna, and Murthy Saravana
- Subjects
Oncology ,medicine.medical_specialty ,Plasma Gases ,Cancer therapy ,FOLFIRINOX ,Science ,Leucovorin ,Irinotecan ,01 natural sciences ,Article ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,0103 physical sciences ,medicine ,Adjuvant therapy ,Humans ,Survival rate ,010302 applied physics ,Multidisciplinary ,Dose-Response Relationship, Drug ,business.industry ,Drug Synergism ,Bile duct cancer ,Chemotherapy regimen ,Oxaliplatin ,Fluorouracil ,030220 oncology & carcinogenesis ,Medicine ,Folfirinox Regimen ,business ,medicine.drug - Abstract
Cholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is a possible treatment for severe CCA cases. A limitation of this chemotherapy regimen is its toxicity to patients and adverse events. There exists a need for therapies to alleviate the toxicity of a FOLFIRINOX regimen while enhancing or not altering its anticancer properties. Cold Atmospheric plasma (CAP) is a technology with a promising future as a selective cancer treatment. It is critical to know the potential interactions between CAP and adjuvant chemotherapeutics. In this study the aim is to characterize the efficacy of FOLFIRINOX and CAP in combination to understand potential synergetic effect on CCA cells. FOLFIRINOX treatment alone at the highest dose tested (53.8 nM fluorouracil, 13.1 nM Leucovorin, 5.1 nM Irinotecan, and 3.7 nM Oxaliplatin) reduced CCA cell viability to below 20% while CAP treatment alone for 7 min reduced viability to 3% (p
- Published
- 2021